#Todos #Medical #Corporate #Update
- 3CL Pharma prepares to crowdfund for Long COVID trials of Tollovir™ and Tollovid™
- CEO to Present at Emerging Growth Conference on Wednesday, October 12, 2022 at 2pm ET
New York, NY, and Tel Aviv, ISRAEL, Oct. 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today provided a corporate update for shareholders. The company will give a presentation at the Emerging Growth Conference on Wednesday, October 12, 2022 at 2:00pm EST.
Event: Emerging Growth Conference
Presentation Date: Wednesday October 12, 2022
Time: 2:00pm Eastern Time (ET)
Register to Attend: https://goto.webcasts.com/starthere.jsp?ei=1571724&tp_key=4274f13b29&sti=tomdf
Commercial PCR Testing Business
The Company’s CLIA/CAP-certified clinical testing lab Provista Diagnostics recently completed a successful launch of its suite of PCR testing services for Urinary Tract Infection (UTI), Wound, Respiratory Pathogen (RP), Gastrointestinal (GI) and Sexually Transmitted Infections (STI), COVID and MonkeyPox in Dunnellon, Florida where it onboarded multiple providers including urgent care centers, specialty care practices such as podiatry, skilled nursing facilities and hospitals. The focus of Provista’s commercial operations has transitioned beyond high volume COVID testing towards integrated genetic testing solutions with fast turnaround time and more insightful treatment recommendations. This empowers providers with a PCR biomarker data toolkit that improves patient outcomes and reduces the overall cost of care. Our soft launch was successful and we learned a number of lessons which enable us to prepare marketing collateral for the full-scale launch in the broader rural area around Dunnellon which is also underserved by the major lab testing companies. Once this full-scale launch is complete, we intend to duplicate this effort in other strategic rural underserved areas around the United…
